Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Friday 9 January 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Digital

medicines and smartphone

Molecules, DTx, and a breakthrough in chronic cough

Early evidence for a cough treatment digital therapeutic is compelling.

Sales & Marketing

Discussion in an HCP office about possibilities

HSA growth and the opportunities emerging for investors and ...

Paying attention to the intersection of public policy and business opportunity can be a winning strategy for start-ups and disrupters.

Market Access

ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ...

At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.

Sales & Marketing

Pharmacist with patient, explaining prescription

Why pharmacy-based engagement is pharma’s untapped adherence...

Pharma companies can work alongside pharmacists to deliver personalised outreach that informs patient treatment decisions and drives adherence.

Sales & Marketing

HCP using tablet

Sponsored

To reach HCPs, don’t try to be everywhere. Just be where the...

“Omnichannel” – the marketing strategy buzzword that has pervaded the space in the last several years – literally means “in every channel”; in effect, making sure a brand or message is ever

Patients

Endometriosis hidden suffering and disease burden

Endometriosis: hidden suffering and disease burden

Improving patient outcomes starts by listening to and understanding their needs.

Views & Analysis

vaccines

Overcoming the challenges of developing vaccines in an accel...

The COVID-19 pandemic stopped the world in its tracks.

Views & Analysis

HLTH Main Stage

Roundup: Pharma news from HLTH 2022

Although originally focused more on providers and health tech, the US conference HLTH has been steadily widening its scope and now hosts a wide variety of healthcare stakeholders.

Load more results

Sales & Marketing

Sales & Marketing

Discussion in an HCP office about possibilities

HSA growth and the opportunities emerging for investors and ...

Paying attention to the intersection of public policy and business opportunity can be a winning strategy for start-ups and disrupters.

Sales & Marketing

Pharmacist with patient, explaining prescription

Why pharmacy-based engagement is pharma’s untapped adherence...

Pharma companies can work alongside pharmacists to deliver personalised outreach that informs patient treatment decisions and drives adherence.

Digital

Digital

medicines and smartphone

Molecules, DTx, and a breakthrough in chronic cough

Early evidence for a cough treatment digital therapeutic is compelling.

Digital

lady at computer screen

Sponsored

Clinical trials at the core: Decentralised, AI targeted, ESG...

For Inventus' Steve Sanghera and Jim Michel 2025 was a year of progress in clinical trial enablement.

Market Access

Market Access

ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ...

At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.

Market Access

Group of ethnically diverse women

Women's health: Predictions for 2026

A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.

Editor's Picks

Novo Nordisk launches Wegovy pill at $149 a month

Insilico ends 2025 with $293m Hong Kong IPO

Judge blocks HHS' 340B rebate pilot at 11th hour

CMS aims for broader GLP-1 access via federal programmes

Ipsen licenses Simcere ADC in $1bn-plus deal

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

pharmaphorum podcast Episode 238, Andrew Newland, ANGLE

Aligning with national efforts to modernise cancer diagnosti...

Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Oncology

Cancer cell on pink background

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Patients

Patients

Patient in hospital bed, engaged with care information

Moving beyond the pill: Unlocking value through engaged, emp...

Creating an environment where the patient is recognised as an active participant in their care journey is critical.

Patients

the role of digital in the patient journey

Putting patients first: 5 strategic shifts making clinical t...

From gamified digital platforms to remote sample collection and agile site activation, sponsors are reimagining trial design.

Patients

Physician with gloved hands holds a patient's hands with CHE

Prioritising dermatology to reduce pressure on healthcare se...

Chronic skin conditions, particularly CHE, remain some of the most underestimated, yet pervasive, challenges affecting people across Europe.

R&D

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

R&D

Handshake to seal a deal in the City

Closed & Collaborative H2 2025: Mergers, acquisitions, partn...

The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.

R&D

AI use in clinical trials

From complexity to cohesion: AI’s growing role in building s...

AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.

Editor's Picks

Novo Nordisk launches Wegovy pill at $149 a month

Insilico ends 2025 with $293m Hong Kong IPO

Judge blocks HHS' 340B rebate pilot at 11th hour

CMS aims for broader GLP-1 access via federal programmes

Ipsen licenses Simcere ADC in $1bn-plus deal

News

J&J chief executive Joaquin Duato

J&J jumps on the MFN pricing train

Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company